Page 187 of 1,034: studies 1,861 to 1,870 of 10,336, newest first. Back to the depression overview
Psychology Research and Behavior Management February 8, 2023
Negative Bias or Positive Deficiency, or Both? The Relationship Between Individual Authenticity and Depression Among Preschool Teachers: The Sequential Mediation Effects of Mindfulness and Self-Alienation.
Behavioral Sleep Medicine February 6, 2023 Ebrahim Norouzi, Leeba Rezaie, A. Bender et al.
ABSTRACT Background As the disorder progresses, patients with depression suffer from decreased emotional stability, cognitive control and motivation. In the present study, we examined the effectiveness of three interventions on emotion dysregulation and insomnia severity: 1) mindfulness; 2) physical activity, and 3) mindfulness plus physical activity. Method A total of 50 participants (mean age...
Journal of Affective Disorders February 3, 2023 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 168 citations
Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.
Frontiers in Neuroscience February 2, 2023 Haiyan Liu, Chengyu Wang, Xiaofeng Lan et al.
Background Dysfunction of the amygdala is the core pathogenesis of major depressive disorder (MDD). However, it remains unclear whether ketamine treatment could modulate characteristics of amygdala-related networks. We aimed to explore the relationship between changes in the resting-state functional connectivity (RSFC) of the amygdala and the treatment of ketamine in MDD patients and to...
Comprehensive Psychiatry February 1, 2023 L. Leng, Xi-Can Yin, S. Ng
OBJECTIVES About one in four mothers will experience depression and anxiety during pregnancy and within their first year following childbirth. The meta-analysis aggregated the findings of randomized controlled trials (RCTs) evaluating the immediate post-intervention and maintenance effects of MBI on perinatal depression and anxiety. METHODS A systematic search was conducted in PubMed, PsycINFO,...
Brain Science February 1, 2023 Ahmed Hasbi, Bertha K. Madras, S. George
Background: There is a growing liberalization of cannabis-based preparations for medical and recreational use. In multiple instances, anxiety and depression are cited as either a primary or a secondary reason for the use of cannabinoids. Aim: The purpose of this review is to explore the association between depression or anxiety and the dysregulation of the endogenous endocannabinoid system...
The Brown University Psychopharmacology Update February 1, 2023
Results of a systematic review and meta‐analysis comprising six clinical trials suggest that electroconvulsive therapy (ECT) is more efficacious than ketamine in reducing the severity of depressive symptoms in patients with a major depressive episode. No significant between‐group differences in the prevalence of adverse events were observed. Results of the meta‐analysis were published online...
Pharmaceuticals February 1, 2023 Agnieszka Pałucha-Poniewiera, B. Bobula, Anna Rafało-Ulińska
(S)-Ketamine is the first rapid-acting antidepressant drug (RAAD) introduced for the treatment of depression. However, research is still being carried out on the search for further RAADs that will be not only effective but also safe to use. Recent data have indicated that the combined administration of (R)-ketamine and the mGlu2/3 receptor antagonist LY341495 (mixRL) induces rapid and sustained...
Journal of Affective Disorders February 1, 2023 Li-Gang Zhang, Ling-Fei Cheng, Ting-Ting Wang et al.
The study explored the differences in nightmare, insomnia, depression, anxiety, and cognitive deficits among adolescents and the chain mediating effects of insomnia, depression, and anxiety on the relationship between nightmares and cognitive deficits in adolescents. An online survey was used to collect demographic data of 6014 adolescents and assess nightmare, insomnia, depression, anxiety,...
Neuropharmacology February 1, 2023 Yu-Jung Cheng, Chieh-Hsin Lin, Hsien-Yuan Lane
Studies have demonstrated the beneficial therapeutic effects of sarcosine, benzoate, and ketamine (including esketamine and arketamine) on depression. These drugs mainly act by modulating N-methyl-d-aspartate glutamate receptors (NMDARs) and reducing inflammation in the brain. Although ketamine, benzoate, and sarcosine act differently as the antagonists or coagonists of NMDARs, they all have...